Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.

Emadi A, Jun SA, Tsukamoto T, Fathi AT, Minden MD, Dang CV.

Exp Hematol. 2014 Apr;42(4):247-51. doi: 10.1016/j.exphem.2013.12.001. Epub 2013 Dec 11.

PMID:
24333121
2.

Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.

Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, Tsukamoto T, Rojas CJ, Slusher BS, Rabinowitz JD, Dang CV, Riggins GJ.

Cancer Res. 2010 Nov 15;70(22):8981-7. doi: 10.1158/0008-5472.CAN-10-1666. Epub 2010 Nov 2.

3.

IDH mutations in glioma and acute myeloid leukemia.

Dang L, Jin S, Su SM.

Trends Mol Med. 2010 Sep;16(9):387-97. doi: 10.1016/j.molmed.2010.07.002. Epub 2010 Aug 5. Review.

PMID:
20692206
4.

Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.

Boutzen H, Saland E, Larrue C, de Toni F, Gales L, Castelli FA, Cathebas M, Zaghdoudi S, Stuani L, Kaoma T, Riscal R, Yang G, Hirsch P, David M, De Mas-Mansat V, Delabesse E, Vallar L, Delhommeau F, Jouanin I, Ouerfelli O, Le Cam L, Linares LK, Junot C, Portais JC, Vergez F, Récher C, Sarry JE.

J Exp Med. 2016 Apr 4;213(4):483-97. doi: 10.1084/jem.20150736. Epub 2016 Mar 7.

5.

IDH mutations in cancer and progress toward development of targeted therapeutics.

Dang L, Yen K, Attar EC.

Ann Oncol. 2016 Apr;27(4):599-608. doi: 10.1093/annonc/mdw013. Review.

PMID:
27005468
6.

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.

DiNardo CD, Propert KJ, Loren AW, Paietta E, Sun Z, Levine RL, Straley KS, Yen K, Patel JP, Agresta S, Abdel-Wahab O, Perl AE, Litzow MR, Rowe JM, Lazarus HM, Fernandez HF, Margolis DJ, Tallman MS, Luger SM, Carroll M.

Blood. 2013 Jun 13;121(24):4917-24. doi: 10.1182/blood-2013-03-493197. Epub 2013 May 2.

7.

Effect of lysine to alanine mutations on the phosphate activation and BPTES inhibition of glutaminase.

McDonald CJ, Acheff E, Kennedy R, Taylor L, Curthoys NP.

Neurochem Int. 2015 Sep;88:10-4. doi: 10.1016/j.neuint.2014.12.003. Epub 2014 Dec 12.

8.

[Clinical characteristics in adult acute myeloid leukemia with isocitrate dehydrogenase gene mutation].

Wang RX, Wu DP, Chen SN, He J, Xu Y, Wang XL, Yin J, Tian H, Tian XP, Sun AN.

Zhonghua Yi Xue Za Zhi. 2013 Mar 12;93(10):751-5. Chinese.

PMID:
23755812
9.

Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.

Chen C, Liu Y, Lu C, Cross JR, Morris JP 4th, Shroff AS, Ward PS, Bradner JE, Thompson C, Lowe SW.

Genes Dev. 2013 Sep 15;27(18):1974-85. doi: 10.1101/gad.226613.113.

10.

Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia.

Fathi AT, Wander SA, Faramand R, Emadi A.

Semin Hematol. 2015 Jul;52(3):165-71. doi: 10.1053/j.seminhematol.2015.03.002. Epub 2015 Mar 17. Review.

PMID:
26111463
11.

The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.

Nassereddine S, Lap CJ, Haroun F, Tabbara I.

Ann Hematol. 2017 Dec;96(12):1983-1991. doi: 10.1007/s00277-017-3161-0. Epub 2017 Oct 31. Review.

PMID:
29090344
12.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K.

J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.

PMID:
20567020
13.

Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.

Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsen R, Willems L, Saland E, Decroocq J, Maciel TT, Lambert M, Poulain L, Hospital MA, Sujobert P, Joseph L, Chapuis N, Lacombe C, Moura IC, Demo S, Sarry JE, Recher C, Mayeux P, Tamburini J, Bouscary D.

Blood. 2015 Sep 10;126(11):1346-56. doi: 10.1182/blood-2015-01-621870. Epub 2015 Jul 17.

14.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2010 May 10;28(14):2348-55. doi: 10.1200/JCO.2009.27.3730. Epub 2010 Apr 5.

15.

IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.

Yamaguchi S, Iwanaga E, Tokunaga K, Nanri T, Shimomura T, Suzushima H, Mitsuya H, Asou N.

Eur J Haematol. 2014 Jun;92(6):471-7. doi: 10.1111/ejh.12271. Epub 2014 Mar 3.

PMID:
24443894
16.

Isocitrate dehydrogenase mutations in myeloid malignancies.

Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R.

Leukemia. 2017 Feb;31(2):272-281. doi: 10.1038/leu.2016.275. Epub 2016 Oct 10. Review.

17.

[Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].

Jia ZX, Zhou M, Chao HY, Lu XZ, Zhang R, Cen L, Xiao R, Jiang NK.

Zhonghua Xue Ye Xue Za Zhi. 2012 May;33(5):397-401. Chinese.

PMID:
22781800
18.

IDH2 inhibition in AML: Finally progress?

Stein EM.

Best Pract Res Clin Haematol. 2015 Jun-Sep;28(2-3):112-5. doi: 10.1016/j.beha.2015.10.016. Epub 2015 Oct 19. Review.

PMID:
26590767
19.

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.

DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, Routbort M, Patel KP, Mark Brandt, Pierce S, Garcia-Manero G, Cortes J, Kantarjian H.

Am J Hematol. 2015 Aug;90(8):732-6. doi: 10.1002/ajh.24072.

20.

Metabolic consequences of oncogenic IDH mutations.

Parker SJ, Metallo CM.

Pharmacol Ther. 2015 Aug;152:54-62. doi: 10.1016/j.pharmthera.2015.05.003. Epub 2015 May 5. Review.

Supplemental Content

Support Center